Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript
Lo studio di rademikibart per la dermatite atopica di Simcere selezionato per la presentazione all’AAD
Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Connect Biopharma Hldgs (NASDAQ:CNTB), Immuneering (NASDAQ:IMRX)